Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M24D1 in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
NCT07255898Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M24D1 in multiple myeloma (MM) and hematologic malignancy, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
BL-M24D1
03
Conditions
multiple myeloma (MM)hematologic malignancy
Beyond the preview
Go deeper on NCT07255898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255898.